Related Experiment Videos
Multidrug resistant transgenic mice as a novel pharmacologic tool
G H Mickisch1, I Pastan, M M Gottesman
1Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.
Summary
Scientists engineered a transgenic mouse to combat multidrug resistance in cancer therapy. This new animal model enables rapid drug screening to inhibit the multidrug transporter, improving chemotherapy effectiveness.
Area of Science:
- Biotechnology
- Pharmacology
- Oncology
Background:
- Multidrug resistance (MDR) in cancer is often mediated by efflux pumps like the one encoded by the human MDR1 gene.
- This resistance significantly hinders the efficacy of conventional chemotherapy.
- Developing effective animal models for studying MDR and screening inhibitors has been challenging and costly.
Purpose of the Study:
- To develop a novel transgenic animal model for studying multidrug resistance in cancer.
- To facilitate the rapid screening of pharmacologic agents that inhibit multidrug transporters.
- To overcome limitations associated with current animal models in drug development for cancer therapy.
Main Methods:
- Utilized recombinant DNA technology to create a transgenic mouse model.
- Engineered the mouse to express the human MDR1 gene.
- The expression of MDR1 in bone marrow confers protection against chemotherapy toxicity.
Main Results:
- Successfully generated a transgenic mouse model expressing the MDR1 gene.
- Demonstrated that bone marrow in these mice is protected from chemotherapy's toxic effects.
- Established a system for the rapid screening of drugs targeting multidrug transporters.
Conclusions:
- The developed transgenic mouse model offers a valuable platform for pharmacologic screening.
- This innovation represents a significant advancement in developing strategies to overcome multidrug resistance in cancer.
- Transgenic animal models are poised to revolutionize drug discovery and development in oncology.